Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger
The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital's shell company Concentra Biosciences, clearing up any doubt about its pending merger with Alumis. Acelyrin's shares {$SLRN} were ...
The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital's shell company Concentra Biosciences, clearing up any doubt about its pending merger with Alumis.
Acelyrin's shares {$SLRN} were ...
